# Incidental Germline Findings from Tumor Sequencing

## Overview

Somatic tumor sequencing increasingly identifies germline pathogenic variants as an unintended byproduct of testing. An estimated 3-18% of patients undergoing tumor genomic profiling harbor reportable germline pathogenic variants, depending on the panel and patient population. The most commonly identified genes include BRCA1/2, Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), ATM, CHEK2, and PALB2. Discovery of these variants has implications for the patient's cancer management, their future cancer risk, and risk for biological relatives, while raising complex issues around informed consent, disclosure obligations, and follow-up infrastructure.

## Frequency and Spectrum of Germline Findings

### Prevalence Data

Large-scale studies (MSK-IMPACT, TCGA, AACR GENIE) demonstrate germline pathogenic variants in approximately 4-8% of unselected cancer patients. Rates are higher in specific tumor types: ovarian cancer (15-20%), breast (8-10%), prostate (10-15%), and pancreatic (5-10%). Even studies using tumor-only sequencing without intentional germline analysis inadvertently detect germline variants based on VAF patterns. Variants at approximately 50% VAF in tumor-only testing raise suspicion for germline origin, though tumor purity and copy number alterations can confound this interpretation.

| Tumor Type | Frequency of Germline PVs | Most Commonly Identified Genes |
|---|---|---|
| Ovarian cancer | 15–20% | BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 |
| Prostate cancer | 10–15% | BRCA2, ATM, CHEK2, HOXB13 |
| Breast cancer | 8–10% | BRCA1, BRCA2, PALB2, CHEK2, ATM |
| Pancreatic cancer | 5–10% | BRCA2, ATM, PALB2, CDKN2A |
| Colorectal cancer | 5–8% | MLH1, MSH2, MSH6, PMS2, APC |
| Unselected solid tumors | 4–8% | BRCA1/2, Lynch genes, ATM, CHEK2, TP53 |

### Most Commonly Identified Genes

BRCA1 and BRCA2 are the most frequently identified, especially in ovarian, breast, prostate, and pancreatic cancers. Lynch syndrome genes appear prominently in colorectal, endometrial, and ovarian cancers. ATM, CHEK2, and PALB2 represent moderate-penetrance breast and pancreatic cancer genes. TP53 must be carefully distinguished from somatic TP53 mutations (which are extremely common in tumors) and from CHIP. SDH subunit genes emerge in pheochromocytoma, paraganglioma, and GIST. RET, VHL, APC, and MEN1 appear in endocrine and GI tumors.

<image>Bar graph showing the frequency of incidental germline pathogenic variants by gene across different tumor types based on large-scale tumor genomic profiling studies</image>

## Challenges in Identifying Germline Variants from Tumor Sequencing

### Tumor-Only vs. Paired Tumor-Normal Sequencing

Tumor-only sequencing cannot definitively distinguish germline from somatic variants. High VAF variants near 50% may be germline, but loss of heterozygosity in the tumor can elevate somatic variant VAF to similar levels. Population database filtering helps but is imperfect for underrepresented populations, and there is a risk of failing to identify germline variants if they are filtered out as presumed population polymorphisms. Paired tumor-normal sequencing represents the gold standard, with germline variants present in the normal sample at approximately 50% VAF. Some platforms like MSK-IMPACT intentionally analyze both somatic and germline significance.

### Confounding Factors

Clonal hematopoiesis (CHIP) produces somatic mutations in blood cells at moderate VAF that may mimic germline variants when blood serves as the normal comparator. Loss of heterozygosity in the tumor can make a heterozygous germline variant appear at higher VAF or can lose the mutant allele entirely. Low tumor purity can reduce apparent VAF of somatic mutations, making them appear germline. Low-level germline mosaicism may be missed if below detection thresholds.

## Consent and Disclosure

### Pre-Test Considerations

Informed consent for tumor genomic profiling should address the possibility of incidental germline findings. Consent models vary across institutions and include opt-in (patient actively chooses to receive germline results), opt-out (germline results reported unless declined), mandatory disclosure (all clinically significant findings reported regardless of preference), and no germline analysis models. ASCO and ACMG recommend that patients undergoing tumor sequencing be informed about the possibility of germline findings.

### Post-Test Disclosure

When a suspected germline variant is identified from tumor testing, confirmatory germline testing on an independent sample (blood or saliva) is required before any clinical action. Referral to genetic counseling for pre- and post-test counseling follows. If confirmed germline, standard management guidelines for the specific syndrome apply, and cascade testing is offered to at-risk relatives. Laboratories differ in whether they flag suspected germline variants in tumor reports.

<image>Decision tree for managing suspected germline findings from tumor genomic profiling, from initial identification through confirmatory testing, genetic counseling, and cascade testing of family members</image>

### Ethical Obligations

Clinicians have a duty to inform patients of medically actionable germline findings. An ethical (though not always legal) obligation exists regarding at-risk relatives, varying by jurisdiction. The right not to know must be balanced against medical actionability. Some germline findings may be incidental to the cancer being treated, such as a BRCA2 mutation discovered during colon cancer profiling.

## Clinical Impact of Germline Findings

### Therapeutic Implications

BRCA1/2 germline variants confer PARP inhibitor eligibility (olaparib, rucaparib, niraparib) in ovarian, breast, prostate, and pancreatic cancers. Lynch syndrome (MMR gene) variants predict immune checkpoint inhibitor response in MSI-H tumors and influence surgical decisions. The broader homologous recombination deficiency gene set (BRCA1/2, PALB2, RAD51C/D, BRIP1) may predict PARP inhibitor sensitivity. Germline status may also influence clinical trial eligibility.

### Surveillance and Risk Reduction

Confirmed germline variants trigger cancer-specific surveillance protocols for the patient's other cancer risks. For example, BRCA2 identified during prostate cancer profiling triggers breast cancer screening for female relatives and consideration of pancreatic cancer screening. Risk-reducing surgeries may be indicated, such as salpingo-oophorectomy for BRCA carriers.

### Impact on Family

Cascade genetic testing identifies at-risk relatives who may benefit from enhanced surveillance or risk-reducing interventions. However, uptake of cascade testing after tumor-derived germline findings is suboptimal, with only approximately 30-50% of eligible relatives tested. Barriers include patient reluctance to disclose, family estrangement, and lack of systematic follow-up infrastructure.

<image>Infographic showing the cascade from tumor genomic profiling to germline confirmation to cancer surveillance and cascade testing in family members, with statistics on uptake at each step</image>

## Implementation Challenges

### Infrastructure Needs

Genetic counseling services must be integrated into oncology tumor profiling workflows, yet many oncology practices lack sufficient genetic counselor staffing. Alternative delivery models include telephone and telehealth genetic counseling, chatbot-assisted pre-test education, and embedded counselors in molecular tumor boards. Laboratory reporting standards for flagging potential germline variants are not yet uniform.

### Clinician Education

Oncologists ordering tumor genomic profiling may not recognize germline implications, risking that incidental germline findings are overlooked in complex tumor reports. Training programs increasingly incorporate genomics education, and clinical decision support tools in EHR systems can flag potential germline variants for follow-up.

### Laboratory Responsibilities

AMP/ASCO/CAP guidelines recommend that laboratories performing tumor sequencing should maintain a policy on germline variant identification and reporting. If a paired normal sample is sequenced, the lab should evaluate for actionable germline variants in established cancer predisposition genes. Some laboratories offer reflex germline testing when a suspected germline variant is identified in the tumor.

## Clinical Pearls

A BRCA1/2 variant at approximately 50% VAF in tumor-only sequencing warrants germline confirmation regardless of family history, as up to 50% of BRCA carriers do not meet traditional testing criteria. TP53 somatic mutations are found in over 50% of cancers and should not be assumed germline without confirmatory testing, with CHIP also considered. Germline confirmation on an independent sample is mandatory before any clinical action or family testing -- tumor-only results alone are never sufficient. MSI-H tumors should prompt evaluation for Lynch syndrome by checking MLH1 methylation and BRAF V600E to distinguish somatic from germline MMR deficiency. Patients may not recall or understand pre-test consent regarding germline findings, making re-consent and counseling at the time of disclosure important. Even when a germline variant is identified, the patient's immediate oncologic care remains the priority, with germline follow-up coordinated but not urgently delayed.

## References

- Mandelker D, Zhang L, Kemel Y, et al. "Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing." *JAMA*. 2017;318(9):825-835.
- Schrader KA, Cheng DT, Joseph V, et al. "Germline variants in targeted tumor sequencing using matched normal DNA." *JAMA Oncology*. 2016;2(1):104-111.
- Samadder NJ, Ravi V, Gierisch JM, et al. "Prospective evaluation of universal tumor screening for Lynch syndrome in a large healthcare system." *Journal of Clinical Oncology*. 2021;39(suppl 3):2.
- ASCO Policy Statement Update: Germline and somatic testing in cancer care. *Journal of Clinical Oncology*. 2023.
- Robson ME, Bradbury AR, Arun B, et al. "American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility." *Journal of Clinical Oncology*. 2015;33(31):3660-3667.